References
- Carroll CP. Opioid treatment for acute and chronic pain in patients with sickle cell disease. Neurosci Lett. 2020;714:134534.
- Borhade MB, Kondamudi NP. Sickle cell crisis. Treasure Island (FL): StatPearls; 2021.
- Sagi V, Mittal A, Tran H, et al. Pain in sickle cell disease: current and potential translational therapies. Transl Res. 2021: S1931–5244(21)00057-8.
- Baldini A, Von Korff M, Lin EH. A review of potential adverse effects of long-term opioid therapy: a practitioner’s guide. Prim Care Companion CNS Disord. 2012;14:PCC.11m01326.
- Benyamin R, Trescot AM, Datta S, et al. Opioid complications and side effects. Pain Physician. 2018;11(2 Suppl):S105–S120.
- Akbarali HI, Dewey WL. Gastrointestinal motility, dysbiosis and opioid-induced tolerance: is there a link? Nat Rev Gastroenterol Hepatol. 2019;16:323–324.
- Lichtbroun M, Jafri F, Chaudhary RC, et al. High incidence of healthcare facility-acquired Clostridium difficile infections in chronic opioid users. J Intern Med. 2021;289:129–130.
- Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 1998;91:288–294.
- Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med. 1994;330:1639–1644.
- Tran H, Gupta M, Gupta K. Targeting novel mechanisms of pain in sickle cell disease. Blood. 2017;130:2377–2385.